Compare Stocks: LLY, MRNA, and GH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$167.47 +1.2%	$167.74	$61.00 ▼ $191.05	$22.47B	1.58	2.23 million shs	1.52 million shs
LLY Eli Lilly and Company	$1,177.57 +0.7%	$1,174.35	$783.85 ▼ $1,292.65	$1.11T	0.46	2.97 million shs	1.39 million shs
MRNA Moderna	$225.00 +14.2%	$140.07	$22.28 ▼ $225.00	$89.83B	1.09	12.24 million shs	28.85 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	-1.65%	-5.26%	+2.85%	+3.44%	+153.46%
LLY Eli Lilly and Company	-1.45%	+1.64%	+4.11%	-1.62%	+38.34%
MRNA Moderna	+0.26%	+4.27%	+40.38%	+188.56%	+605.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$167.47 +1.2%	$167.74	$61.00 ▼ $191.05	$22.47B	1.58	2.23 million shs	1.52 million shs
LLY Eli Lilly and Company	$1,177.57 +0.7%	$1,174.35	$783.85 ▼ $1,292.65	$1.11T	0.46	2.97 million shs	1.39 million shs
MRNA Moderna	$225.00 +14.2%	$140.07	$22.28 ▼ $225.00	$89.83B	1.09	12.24 million shs	28.85 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	-1.65%	-5.26%	+2.85%	+3.44%	+153.46%
LLY Eli Lilly and Company	-1.45%	+1.64%	+4.11%	-1.62%	+38.34%
MRNA Moderna	+0.26%	+4.27%	+40.38%	+188.56%	+605.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GH Guardant Health	2.96	Moderate Buy	$189.38	13.08% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,313.43	11.54% Upside
MRNA Moderna	2.08	Hold	$78.17	-65.26% Downside

Current Analyst Ratings Breakdown

Latest LLY, MRNA, and GH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,410.00 ➝ $1,440.00
10/7/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,419.00 ➝ $1,430.00
10/7/2026	GH Guardant Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$200.00 ➝ $220.00
10/7/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$89.00 ➝ $95.00
10/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
10/1/2026	GH Guardant Health	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$190.00 ➝ $200.00
9/30/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$60.00 ➝ $80.00
9/28/2026	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,400.00 ➝ $1,500.00
9/25/2026	MRNA Moderna	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/23/2026	MRNA Moderna	Singular Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GH Guardant Health	$1.18B	19.00	N/A	N/A	($0.79) per share	-211.99
LLY Eli Lilly and Company	$65.18B	17.01	$24.90 per share	47.29	$28.07 per share	41.95
MRNA Moderna	$2.21B	40.65	N/A	N/A	$22.14 per share	10.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GH Guardant Health	-$416.28M	-$3.49	N/A	N/A	N/A	-38.33%	N/A	-25.40%	10/28/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.52	25.22	1.46	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)

Latest LLY, MRNA, and GH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	MRNA Moderna	-$1.10	N/A	N/A	N/A	$895.85 million	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$9.83	N/A	N/A	N/A	$22.30 billion	N/A
10/28/2026	Q3 2026	GH Guardant Health	-$0.7526	N/A	N/A	N/A	$350.60 million	N/A
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	GH Guardant Health	-$0.7618	-$0.42	+$0.3418	-$0.90	$314.23 million	$334.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GH Guardant Health	N/A	4.03	3.71
LLY Eli Lilly and Company	1.41	1.35	1.00
MRNA Moderna	0.09	2.29	2.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GH Guardant Health	92.60%
LLY Eli Lilly and Company	82.53%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
GH Guardant Health	5.60%
LLY Eli Lilly and Company	0.14%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GH Guardant Health	2,506	134.20 million	126.68 million	Not Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable

LLY, MRNA, and GH Headlines

Recent News About These Companies

Moderna stock skyrockets on reports of US cancer vaccine initiative

50 minutes ago | msn.com

MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push

50 minutes ago | finance.yahoo.com

The science and politics of the new mRNA flu vaccine

October 9 at 2:20 PM | sciencefriday.comS

Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines

October 9 at 2:20 PM | finance.yahoo.com

Moderna stock fires past 52-week high: what's behind Friday's rally?

October 9 at 2:20 PM | msn.com

Moderna stock jumps on planned national cancer vaccine effort

October 9 at 2:20 PM | finance.yahoo.com

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

October 9 at 1:59 PM | 247wallst.com

Moderna, Inc. $MRNA Shares Sold by Douglas Lane & Associates LLC

October 9 at 1:08 PM | marketbeat.com

Top Healthcare Stocks To Research - October 9th

October 9 at 1:01 PM | marketbeat.com

Biotech Stocks To Follow Today - October 9th

October 9 at 12:01 PM | marketbeat.com

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

October 9 at 11:48 AM | 247wallst.com

Moderna (NASDAQ:MRNA) Shares Up 8.3% - Here's Why

October 9 at 11:39 AM | marketbeat.com

Moderna's Factory Floor Becomes the Real Battleground After 555% Run

October 9 at 7:50 AM | ad-hoc-news.deA

Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?

October 9 at 3:31 AM | insidermonkey.com

Moderna Builds the Back Office for a Cancer Franchise as Insiders Trim Holdings

October 9 at 2:49 AM | ad-hoc-news.deA

Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?

October 9 at 2:49 AM | finance.yahoo.com

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

October 9 at 2:49 AM | finance.yahoo.com

Rep. Maria Elvira Salazar Unloads Shares of Moderna, Inc. (NASDAQ:MRNA)

October 9 at 2:00 AM | marketbeat.com

Biotech Stocks To Follow Now - October 7th

October 9 at 1:03 AM | americanbankingnews.com

Moderna's Next Test: Manufacturing a Cancer Franchise at Scale

October 8 at 4:48 PM | ad-hoc-news.deA

Moderna (MRNA) Gets a Hold from Morgan Stanley

October 8 at 4:48 PM | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, MRNA, and GH Company Descriptions

Guardant Health NASDAQ:GH

$167.47 +1.91 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$167.75 +0.28 (+0.17%)

As of 07:57 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Eli Lilly and Company NYSE:LLY

$1,177.57 +7.97 (+0.68%)

Closing price 03:59 PM Eastern

Extended Trading

$1,177.40 -0.17 (-0.01%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Moderna NASDAQ:MRNA

$225.00 +28.00 (+14.21%)

Closing price 04:00 PM Eastern

Extended Trading

$225.45 +0.45 (+0.20%)

As of 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, MRNA, and GH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, MRNA, and GH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, MRNA, and GH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, MRNA, and GH Company Descriptions

Guardant Health NASDAQ:GH

Eli Lilly and Company NYSE:LLY

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, MRNA, and GH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, MRNA, and GH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, MRNA, and GH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, MRNA, and GH Company Descriptions

Guardant Health NASDAQ:GH

Eli Lilly and Company NYSE:LLY

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools